This site uses cookies to collect activity data and personalize content. By continuing to navigate this site, you agree to allow us to collect information using cookies. Learn more about how we care for your data in our privacy notice.


Single-Dose HPV Vaccination: Current Evidence

The World Health Organization’s (WHO) Strategic Advisory Group of Experts (SAGE) on Immunization concluded that a single dose of human papillomavirus (HPV) vaccine delivers solid protection against HPV. Based on the available evidence, SAGE advised that countries may now choose between a one- or two-dose schedule for 9–14-year-old girls and women aged 15 to 20. This is a major step toward reaching the WHO’s global strategy to accelerate the elimination of cervical cancer.

The following resource provides background on HPV and cervical cancer, HPV vaccines, and the current evidence and potential impact for a single-dose regimen.

Publication date: April 2022

Single-Dose HPV Vaccination: Current Evidence

View Resource